These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32954565)

  • 21. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
    Santoro A; Genov G; Spooner A; Raine J; Arlett P
    Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacovigilance in pharmaceutical companies: An overview.
    Mammì M; Citraro R; Torcasio G; Cusato G; Palleria C; di Paola ED
    J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S33-7. PubMed ID: 24347978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
    Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
    Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential Procedural Efficiencies and Challenges of Combining Multiple Type II Variations into a Single EU-RMP.
    Marshall R; Atuah KN; Tekumalla SH
    Pharmaceut Med; 2020 Feb; 34(1):1-5. PubMed ID: 32048215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
    Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
    Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacovigilance Discussion Forum--The European Generic Medicines Association's 8th Annual Meeting (January 21, 2015--London, UK).
    Lam S
    Drugs Today (Barc); 2015 Jan; 51(1):89-92. PubMed ID: 25685861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Egberts TC; Blackburn S; Persson I; Leufkens HG
    Drug Saf; 2009; 32(12):1175-87. PubMed ID: 19916584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
    Hirota S; Yamaguchi T
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Communication and the Pharmaceutical Industry: what is the reality?
    Edwards B; Chakraborty S
    Drug Saf; 2012 Nov; 35(11):1027-40. PubMed ID: 23061779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Interpretation of Guidelines on Good Pharmacovigilance Practices for European Union].
    Xie YM; Tian F
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2963-8. PubMed ID: 24471312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006-2015.
    Rubino A; Artime E
    Expert Opin Drug Saf; 2017 Aug; 16(8):877-884. PubMed ID: 28548608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The new EU legislation on pharmacovigilance and changing models for drug development.
    Callréus T
    Drug Saf; 2011 Jun; 34(6):529-30; author reply 530-1. PubMed ID: 21585224
    [No Abstract]   [Full Text] [Related]  

  • 37. Key pharmacovigilance stakeholders' experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union.
    Inácio P; Cavaco A; Allan E; Airaksinen M
    Public Health; 2018 Feb; 155():119-128. PubMed ID: 29346070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register.
    Farcas A; Huruba M; Mogosan C
    Br J Clin Pharmacol; 2019 Mar; 85(3):476-491. PubMed ID: 30497102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
    Lane S; Lynn E; Shakir S
    BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.